GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31
Grace Therapeutics, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.88−0.01 (-0.53%)
Close on Oct 19, 2026
- Market cap
- $32.47M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2026
Gross margin
–
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | – | -57.3% | -11.9% | |
| Return on assets | – | -46.1% | -11.2% | |
| Current ratio | – | 39.50 | 8.10 | |
| Diluted shares | 0M | 2M | 17M |
Cash use needs five years of cash flow figures
Grace Therapeutics does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-9.8%
×Asset turnover1.05×
×Equity multiplier1.17×
=Return on equity, FY2022-12.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2022 | -9.8% | 1.05× | 1.17× | -12.0% |
| FY2021 | -10039.8% | 0.00× | 1.24× | -57.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
1of 6 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-$7.79M
- Cash generatingOperating cash flow above zero-$8.87M
- Return on assets improvedROA up on the prior year-13.1% → -10.8%
- Earnings backed by cashOperating cash flow above net income-$8.87M vs -$7.79M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose11.77 → 8.10
- No dilutionShare count did not rise12M → 17M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –